Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab with Chemoradiation in High-Risk Head and Neck Cancer
NCT00791141Phase 2Completed
- Sponsor
- Heinrich Heine University Düsseldorf
- Start
- Aug 2008
- Primary completion
- Apr 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of KL-140 in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Heinrich Heine University Düsseldorf. Primary endpoint: Rate of patients experiencing grade 3/4 acute toxicities combined with 2-years disease-free survival rate. Started Aug 2008; status: completed.
02
Drugs
KL-140
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00791141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00791141.